Rotigotine

Phase 3Completed

2 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Early-Stage Parkinson's Disease

Conditions

Early-Stage Parkinson's Disease

Trial Timeline

Jun 1, 2002 → Nov 1, 2008

NCT ID

NCT00594165

About Rotigotine

Rotigotine is a phase 3 stage product being developed by UCB for Early-Stage Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00594165. Target conditions include Early-Stage Parkinson's Disease.

What happened to similar drugs?

1 of 5 similar drugs in Early-Stage Parkinson's Disease were approved

Approved (1) Terminated (1) Active (4)

✅Rasagiline + PramipexoleLundbeckApproved

🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3

🔄Tamoxifen alone + Tamoxifen + AminoglutethimideAstraZenecaPhase 3

🔄Cyclophosphamide + Methotrexate + Fluorouracil implant + Goserelin + TamoxifenAstraZenecaPhase 3

🔄ABP 234 + PembrolizumabAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03103919	Approved	Completed	Mar 16, 2017	Jan 2, 2018	Parkinson´s Disease
NCT01976871	Approved	Completed	Aug 1, 2014	Dec 1, 2015	Restless Legs Syndrome
NCT01782222	Approved	Completed	Feb 1, 2013	Mar 1, 2014	Idiopathic Parkinson's Disease
NCT01723904	Phase 3	Completed	Oct 1, 2012	Apr 1, 2013	Advanced Parkinson's Disease
NCT01711866	Approved	Completed	Sep 1, 2012	Mar 1, 2013	Advanced Idiopathic Parkinson's Disease
NCT01569464	Phase 3	Completed	Mar 1, 2012	Apr 1, 2013	Restless Legs Syndrome
NCT01498120	Phase 2	Completed	Dec 1, 2011	Dec 1, 2015	Restless Legs Syndrome
NCT01495793	Phase 2	Completed	Dec 1, 2011	May 1, 2014	Restless Legs Syndrome
NCT01300819	Approved	Completed	Feb 1, 2011	Nov 1, 2012	Idiopathic Parkinson's Disease
NCT00594464	Approved	Completed	Sep 1, 2007	May 1, 2008	Parkinson's Disease
NCT00593606	Phase 3	Completed	Jul 1, 2007	Dec 1, 2007	Parkinson's Disease
NCT00519532	Phase 3	Terminated	Jul 1, 2007	May 1, 2009	Parkinson's Disease
NCT00474058	Phase 3	Completed	May 1, 2007	Mar 1, 2009	Parkinson's Disease
NCT01964573	Phase 1	Completed	Dec 1, 2006	Feb 1, 2007	Parkinson's Disease
NCT00498108	Phase 3	Completed	Jan 1, 2006	Sep 1, 2007	Idiopathic Restless Legs Syndrome
NCT00263068	Phase 3	Completed	Dec 1, 2005	Dec 1, 2007	Restless Legs Syndrome
NCT00275236	Phase 3	Completed	Nov 1, 2005	Jul 1, 2006	Restless Legs Syndrome
NCT00135993	Phase 3	Completed	May 1, 2005	Nov 1, 2006	Restless Legs Syndrome
NCT00136045	Phase 3	Completed	May 1, 2005	Aug 1, 2006	Restless Legs Syndrome
NCT00505687	Phase 3	Completed	Feb 1, 2005	Dec 1, 2008	Idiopathic Parkinson's Disease

Competing Products

9 competing products in Early-Stage Parkinson's Disease

See all competitors

Product	Company	Stage	Hype Score
Anastrozole + Trastuzumab Deruxtecan	Daiichi Sankyo	Phase 2	42
ICG	Johnson & Johnson	Pre-clinical	26
SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab Injection	Jiangsu Hengrui Medicine	Phase 3	47
Tamoxifen alone + Tamoxifen + Aminoglutethimide	AstraZeneca	Phase 3	40
Cyclophosphamide + Methotrexate + Fluorouracil implant + Goserelin + Tamoxifen	AstraZeneca	Phase 3	40
ABP 234 + Pembrolizumab	Amgen	Phase 3	47
UCB0599 + Placebo	UCB	Phase 2	35
Rasagiline + Pramipexole	Lundbeck	Approved	32
Neratinib + Loperamide + Colesevelam	Puma Biotechnology	Phase 2	29